EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

361 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-03

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the predictive value (in terms of remission) of a new technique for detecting circulating, functional, prostate cells among patients with localized adenocarcinoma of the prostate, and prior to any treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk

NCT03417336

To Evaluate the Rate of Digestive and Urinary Toxicity

RECRUITING NA

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

NCT07325721

Prostate Cancer Prostate Cancer Patients Treated by Radiotherapy

RECRUITING PHASE2

Evaluation of Different Methods of Ultrasound Image Analysis for Real-time Monitoring of HIFU Prostate Cancer Treatment

NCT05714774

Prostatic Neoplasms

RECRUITING NA

Hypofractionated Stereotactic Boost in Prostate Cancer

NCT01596816

Cancer

COMPLETED PHASE2

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

NCT03581500

Prostate Adenocarcinoma PSA Level Greater Than Ten Stage IIB Prostate Cancer AJCC v8 +7 more

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adenocarcinoma of the Prostate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All study patients

All patients included according to stated inclusion and exclusion criteria.

EPISPOT detection of the number of circulating cells

Intervention Type BIOLOGICAL

EPISPOT detection of the number of circulating, functional, prostate cells per unit blood

CellSearch detection of the number of circulating, functional, prostate cells

Intervention Type BIOLOGICAL

CellSearch detection of the number of circulating, functional, prostate cells per unit blood

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EPISPOT detection of the number of circulating cells

EPISPOT detection of the number of circulating, functional, prostate cells per unit blood

Intervention Type BIOLOGICAL

CellSearch detection of the number of circulating, functional, prostate cells

CellSearch detection of the number of circulating, functional, prostate cells per unit blood

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* Histologically proven presence of prostate adenocarcinoma
* Localized disease on digital rectal examination
* Cancer without extensions
* Acceptance of a curative treatment by the patient

Exclusion Criteria

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient is taking a hormone-modifying treatment
* Patient taking adrogenic supplements

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No